| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Ultragenyx Pharmaceutical (NASDAQ:RARE) reported its Q4 earnings results on Thursday, February 15, 2024 at 04:01 PM.
Here's what investors need to know about the announcement.
Ultragenyx Pharmaceutical beat estimated earnings by 6.17%, reporting an EPS of $-1.52 versus an estimate of $-1.62.
Revenue was up $24.04 million from the same period last year.
Last quarter the company missed on EPS by $0.17 which was followed by a 6.09% increase in the share price the next day.
Here's a look at Ultragenyx Pharmaceutical's past performance:
| Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|
| EPS Estimate | -2.06 | -2.11 | -1.98 | -2.14 |
| EPS Actual | -2.23 | -2.25 | -2.33 | -2.16 |
| Revenue Estimate | 110.02M | 105.20M | 104.69M | 105.12M |
| Revenue Actual | 98.05M | 108.31M | 100.50M | 103.35M |
To track all earnings releases for Ultragenyx Pharmaceutical visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: RARE
